Successful treatment of recurrent metastatic nasopharyngeal carcinoma with nivolumab: a case report

Cover Page

Cite item

Full Text

Abstract

The study objective is to report a case of successful treatment of disseminated nasopharyngeal carcinoma with nivolumab.

Materials and methods. A 22-year-old male patient was admitted to N.N. Blokhin National Medical Research Center of Oncology with a diagnosis of T3N3M1 stage IV nasopharyngeal carcinoma with bone metastasis. After a course of radical chemoradiotherapy, the patient was found to have cancer progression. Between September 2016 and July 2017, the patient received chemotherapy with 3 lines of drugs, but with no effect. We decided to initiate treatment with PD-1 inhibitors. The patient received nivolumab 3 mg/kg every 2 weeks between July 2017 and March 2018.

Results. Positron emission tomography (September 2018) demonstrated no increased uptake of [18F]-fluorodeoxyglucose in earlier identified cancer foci. Since September 2018, the patient has been in persistent remission without any therapy.

Conclusion. This case report demonstrates high efficacy of PD-1 inhibitors in the treatment of disseminated recurrent nasopharyngeal squamous cell carcinoma, resistant to standard radiotherapy and chemotherapy.

About the authors

Yu. M. Bychkov

Russian Scientific Center of Roentgenoradiology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-0309-639X

86 Profsoyuznaya St., Moscow 117997

Russian Federation

A. M. Mudunov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1255-5700

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

I. M. Gelfand

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: igorgelf@yandex.ru
ORCID iD: 0000-0002-4496-6128

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

B. G. Pkheshkhova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1448-1733

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

O. D. Ryzhova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-8483-0081

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

А. A. Akhundov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-9543-990X

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

V. Z. Dobrokhotova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-5889-392X

Bld. 4, 2 Bol’shaya Pirogovskaya St., Moscow 119991

Russian Federation

М. N. Narimanov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1806-8401

24 Kashirskoe Shosse, Moscow 115478

Russian Federation

References

  1. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359—86. doi: 10.1002/ijc.29210.
  2. Pignon J.P., le Maitre A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014.
  3. Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937—44. doi: 10.1056/NEJMoa032646.
  4. Saloura V., Cohen E.E., Licitra L. et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73(6):1227—39. doi: 10.1007/s00280-014-2459-z.
  5. Mudunov A.M., Narimanov M.N., Safarov D.A. New opportunities for immune therapy in patients with disseminated recurrent squamous cell carcinoma of the head and neck. Opukholi golovy i shei = Head and Neck Tumors 2017;7(2):99—105. (In Russ.). doi: 10.17650/2222-1468-2017-7-2-99-105.
  6. Ferris R.L. Immunology and immunotherapy of head and neck cancer. J Clin Oncol 2015;33(29):3293—304. doi: 10.1200/JC0.2015.61.1509.
  7. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27(4):450—61. doi: 10.1016/j.ccell.2015.03.001.
  8. Li J., Jie H.B., Lei Y. et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015;75(3):508—18. doi: 10.1158/0008-5472.CAN-14-1215.
  9. Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128-38. doi: 10.1158/0008-5472.CAN-12-2606.
  10. Concha-Benavente F., Srivastava R.M., Trivedi S. et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNy that induce PD-L1 expression in head and neck cancer. Cancer Res 2016;76(5):1031—43. doi: 10.1158/0008-5472.CAN-15-2001.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.